CSIMarket
 
Bioventus Inc   (NASDAQ: BVS)
Other Ticker:  
 
 
Price: $10.4200 $0.15 1.461%
Day's High: $10.45 Week Perf: -1.14 %
Day's Low: $ 10.15 30 Day Perf: 17.47 %
Volume (M): 160 52 Wk High: $ 14.38
Volume (M$): $ 1,662 52 Wk Avg: $8.37
Open: $10.34 52 Wk Low: $3.90



 Market Capitalization (Millions $) 680
 Shares Outstanding (Millions) 65
 Employees 500
 Revenues (TTM) (Millions $) 556
 Net Income (TTM) (Millions $) -51
 Cash Flow (TTM) (Millions $) 16
 Capital Exp. (TTM) (Millions $) 1

Bioventus Inc
Bioventus Inc. is a global medical technology company that focuses on orthobiologics and orthopedic solutions. The company develops and manufactures innovative products designed to help patients with musculoskeletal conditions and injuries. These products include treatments for osteoarthritis, joint pain, cartilage damage, and bone fractures. Bioventus has a diverse portfolio of products, including surgical and non-surgical options, as well as drugs and devices. The company is committed to improving patient outcomes and quality of life through its advanced orthopedic solutions.


   Company Address: 4721 Emperor Boulevard Durham 27703 NC
   Company Phone Number: 474-6700   Stock Exchange / Ticker: NASDAQ BVS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BSX   -0.2%    
EW        8.03% 
ISRG   -1.09%    
MDT        1.94% 
SYK   -0.71%    
ZBH        0.11% 
• View Complete Report
   



Product Service News

Bioventus Takes Strategic Leap Offloading Rehabilitation Business to Focus on Core Innovations

Published Thu, Jan 2 2025 2:40 PM UTC

In a significant shift within the landscape of HealthTech, Bioventus Inc. (Nasdaq: BVS), a renowned player in the sector of active healing innovations, has completed the divestiture of its Advanced Rehabilitation business to Accelmed Partners. This strategic maneuver, finalized on January 2, 2025, represents the culmination of a decision previously announced on October 1, 20...

Stock Market Announcement

Bioventus Inc Divests Advanced Rehabilitation Business to Fortify Financial Position Amid Strategic Realignment

Published Tue, Oct 1 2024 1:01 PM UTC

Bioventus Inc. Divests Advanced Rehabilitation Business to Fortify Financial Position Amid Strategic RealignmentIn a pivotal move to streamline operations and enhance its financial stability, Bioventus Inc. (Nasdaq: BVS), a prominent force in active healing and rehabilitation technologies, has announced the sale of its Advanced Rehabilitation business, a division of its subs...

Bioventus Inc

Bioventus Inc Delivers Strong Performance in First Quarter Financial Results2.



Bioventus Inc (Nasdaq: BVS), a renowned global leader in active healing innovations, recently reported its financial results for the three months ended March 30, 2024. The company also announced a significant milestone in the form of Amendment No. 5 to its Credit and Guaranty Agreement. These developments highlight Bioventus' commitment to enhancing its financial structure and positioning itself for continued growth in the field of regenerative medicine.
Financial Results:
During the last five trading days, Bioventus Inc shares experienced a decline, while over the past year, the shares surged by an impressive 315.37%. These fluctuations indicate some short-term market volatility but showcase exceptional long-term growth potential.

Bioventus Inc

Bioventus Inc. Achieves Remarkable Growth in Fiscal Fourth Quarter of 2023

Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, recently announced its fourth quarter and full-year financial results for the year ended December 31, 2023. The company also provided its financial guidance for full-year 2024, indicating a positive outlook for the future.
In addition to its financial achievements, Bioventus made headlines with Amendment No. 5 to its Credit and Guaranty Agreement. This amendment, executed on January 18, 2024, demonstrates the company's commitment to optimizing its financial structure and solidifying its position as a frontrunner in regenerative medicine.

Financing Agreement

Bioventus Enhances Financial and Operational Flexibility through Amendment with Credit Agreement Lenders

Published Thu, Jan 18 2024 9:15 PM UTC



Bioventus Inc. (Bioventus), a renowned global leader in active healing innovations, recently announced a significant milestone in its financial and operational strategies. The company entered into Amendment No. 5 to its Credit and Guaranty Agreement, paving the way for enhanced flexibility and opportunities for growth. With this amendment, Bioventus aims to solidif...







Bioventus Inc's Segments
U S    88.71 % of total Revenue
U S Pain Treatments    40.64 % of total Revenue
U S Restorative Therapies    18.37 % of total Revenue
U S Surgical Solutions    29.7 % of total Revenue
International    11.59 % of total Revenue
International Pain Treatments    4.92 % of total Revenue
International Restorative Therapies    3.24 % of total Revenue
International Surgical Solutions    3.42 % of total Revenue

  Bioventus Inc Outlook

On March 12 2024 the Bioventus Inc provided following guidance

On March 12, 2024, Bioventus Inc. (Nasdaq: BVS), known for its global leadership in developing innovations for active healing, revealed its financial performance for the fourth quarter and full year of 2023. The company also shared its financial projections for the entirety of 2024.

Based on the figures released by Bioventus, the company has shown positive growth and strong financial performance throughout the year 2023. The financial results for the fourth quarter and full year of 2023, which ended on December 31st, indicate that Bioventus has successfully maintained its position as a global leader in active healing solutions.

Moreover, Bioventus has set ambitious financial targets for the yea...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com